

Table 10.1 Selected Kinase Inhibitors in the Market or That Have Entered Clinical Development—cont'd

Type	Target	Agents
Ras/Raf/MEK pathway	PI3K	Small-molecule inhibitors BEZ235 (NVP-BEZ235) Buparlisib (BKM-120) Alpelisib (BYL-719) XL-765 (SAR-245409) GDC-0032 Idelalisib (Zydelig [®])
	PDPK1	Small-molecule inhibitors UCN-01
	AKT	Small-molecule inhibitors A-443654 Perifosine (KRK-0401)
	mTOR	Small-molecule inhibitors Temsirolimus (CCI-779, Torisel [®]) Everolimus (RAD-001, Afinitor [®]) Ridaforolimus (AP-23573) Deferasirox (DBO-1609, Exjade [®])
	SGK1	Small-molecule inhibitor GSK-650394
	Aurora kinases	Small-molecule inhibitors Tozasertib (VX-680, MK-0457) Barasertib (AZD-1152) Danusertib (PHA-739358) AT-9283
	PKC	Small-molecule inhibitors UCN-01 Midostaurin (PKC-412, CGP-41251) Ruboxistaurin (LY-333531, Arxxant [®]) Enzastaurin (LY-317615) Sotrastaurin (AEB071) Bryostatin 1 Antisense oligonucleotide ISIS-3521 (LY-900003, Affinitac [®])
	Pim kinases	Small-molecule inhibitor LGH447
	Ras	Antisense oligonucleotides inhibitor of Ras expression ISIS-2503 Farnesyltransferase inhibitors L-744832 AZD-3409 FTI-276 FTI-277 BMS-214662 Tipifarnib (R-115777, Zarnestra [®]) L-778123 Lonafarnib (SCH-66366) SCH-226374